Volume 27, Number 1—January 2021
Research Letter
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Table 1
Molecular susceptibility sequencing results and therapeutic drug monitoring data from treatment of XDR TB, Florida, USA*
Drug (dose) | Sequencing result | Date drug level drawn | Trough, µg/mL | 2h postdose level, µg/mL | 6h postdose level, µg/mL | Typical peak serum concentration, µg/mL |
---|---|---|---|---|---|---|
Bedaquiline (200 mg MWF) | No atpE (ORF) mutation detected; no Rv0678/mmpR (ORF) mutation detected | 2019 Nov 13 | 0.51 (42.25 h postdose) | 1.40 | 1.42 | 1.2–1.8 (5–6 h postdose, maintenance phase) |
N-monodesmethyl bedaquiline (metabolite) | NT | 2019 Nov 13 | 0.22 (42.25 h postdose) | 0.24 | 0.27 | NT |
Pretomanid (200 mg/d) | NT | 2019 Nov 13 | 2.07 (18.25 h postdose) | 3.43 | 2.98 | 2.3–4.3 (5–6 h postdose, at steady state) |
Linezolid (600 mg/d) | No rplC (ORF aa 84–217) mutation detected; no rrl (nt 2191–2929) mutation detected | 2019 Nov 13 | 7.62 (18.25 h postdose) | 24.15 | 17.88 | 12–26 |
Linezolid (600 mg MWF) | NT | 2020 Mar 12 | <2.00† | 19.04 | 13.6 | 12–26 |
*MWF, Monday/Wednesday/Friday; NT, not tested; ORF, open reading frame; XDR, extensively drug-resistant tuberculosis. †Trough sample was not collected; based on the apparent elimination half-life, the linezolid concentration at 48 h was calculated to be <2 µg/mL, a value associated with minimal toxicity.
Page created: October 28, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.